Current immunotherapy, a strategy that enablesthe immune systemof the body to fight tumors, has shown potential in some patients.19 However, its effectiveness is often limitedby the activation of inhibitory molecules such as CTLA-4 and PD-1,which enable cancer cells to avoid immune detection.19 Treatments including immune cytokines, checkpoint inhibitors,and targeted superantigens have been developed, but their successis inconsistent. The gene discussed is PDCD1; the disease is cancer.